Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCA062 in p-CAD positive solid tumors
NCT02375958Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of PCA062 in triple-negative breast cancer (TNBC), head and neck cancer (HNC) and esophageal cancer, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
PCA062
03
Conditions
triple-negative breast cancer (TNBC)head and neck cancer (HNC)esophageal cancer
Beyond the preview
Go deeper on NCT02375958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375958.